Telavancin Demonstrates Activity against Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Vancomycin, Daptomycin, and Linezolid in Broth Microdilution MIC and One-Compartment Pharmacokinetic/Pharmacodynamic Models

被引:20
作者
Smith, Jordan R. [1 ]
Barber, Katie E. [1 ]
Hallesy, Jessica [1 ]
Raut, Animesh [1 ]
Rybak, Michael J. [1 ,2 ]
机构
[1] Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharm Practice, Antiinfect Res Lab, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Detroit, MI USA
关键词
PHARMACOKINETICS; COLLECTION; PATHOGENS; STRAINS; UPDATE;
D O I
10.1128/AAC.00773-15
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Methicillin-resistant Staphylococcus aureus (MRSA) isolates have arisen with reduced susceptibility to several anti-MRSA agents. Telavancin (TLV), a novel anti-MRSA agent, retains low MICs against these organisms. Our objective was to determine the MICs for TLV, daptomycin (DAP), vancomycin (VAN), and linezolid (LZD) against daptomycin-nonsusceptible (DNS) S. aureus, vancomycin-intermediate S. aureus (VISA), heteroresistant VISA (hVISA), and linezolid-resistant (LZDr) S. aureus. We also evaluated these agents against each phenotype in pharmacokinetic/pharmacodynamic (PK/PD) models. Seventy DNS, 100 VISA, 180 hVISA, and 25 LZDr MRSA isolates were randomly selected from our library and tested to determine their MICs against TLV, DAP, VAN, and LZD via broth microdilution and a Trek panel. Four isolates were randomly selected for 168-h in vitro models to evaluate treatment with TLV at 10 mg/kg of body weight/day, DAP at 10 mg/kg/day, VAN at 1 g every 12 h (q12h), and LZD at 600 mg q12h. The MIC50/90 for TLV, DAP, VAN, and LZD against 70 DNS S. aureus isolates were 0.06/0.125 mu g/ml, 2/4 mu g/ml, 1/2 mu g/ml, and 2/2 mu g/ml, respectively. Against 100 VISA isolates, the MIC50/90 were 0.06/0.125 mu g/ml, 1/1 mu g/ml, 4/8 mu g/ml, and 1/2 mu g/ml, respectively. Against 170 hVISA isolates, the MIC50/90 were 0.06/0.125 mu g/ml, 0.5/1 mu g/ml, 1/2 mu g/ml, and 1/2 mu g/ml, respectively. Against 25 LZDr isolates, the MIC50/90 were 0.03/0.06 mu g/ml, 1/1 mu g/ml, 2/2 mu g/ml, and 8/8 mu g/ml, respectively. The TLV MIC was > 0.125 mu g/ml for 10/365 (2.7%) isolates. In PK/PD models, TLV was universally bactericidal at 168 h and statistically superior to all antibiotics against DNS S. aureus strain R2334. These data further establish the potency of TLV against resistant MRSA. The model data demonstrate in vitro bactericidal activity of TLV against hVISA, VISA, DNS S. aureus, and LZDr S. aureus strains. Further clinical research is warranted.
引用
收藏
页码:5529 / 5534
页数:6
相关论文
共 18 条
[1]   Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers [J].
Benvenuto, Mark ;
Benziger, David P. ;
Yankelev, Sara ;
Vigliani, Gloria .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3245-3249
[2]  
Clinical and Laboratory Standards Institute (CLIS), 2014, M100S24 CLSI
[3]   Pharmacokinetics and tissue penetration of linezolid following multiple oral doses [J].
Gee, T ;
Ellis, R ;
Marshall, G ;
Andrews, J ;
Ashby, J ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1843-1846
[4]   Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus [J].
Higgins, DL ;
Chang, R ;
Debabov, DV ;
Leung, J ;
Wu, T ;
Krause, KA ;
Sandvik, E ;
Hubbard, JM ;
Kaniga, K ;
Schmidt, DE ;
Gao, QF ;
Cass, RT ;
Karr, DE ;
Benton, BM ;
Humphrey, PP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1127-1134
[5]   Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide [J].
Jones, RN ;
Streit, JM ;
Fritsche, TR .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (02) :197-199
[6]   Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations [J].
Leonard, Steven N. ;
Vidaillac, Celine ;
Rybak, Michael J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (07) :2928-2933
[7]   Fluorescence Microscopy Demonstrates Enhanced Targeting of Telavancin to the Division Septum of Staphylococcus aureus [J].
Lunde, Christopher S. ;
Rexer, Charles H. ;
Hartouni, Stephanie R. ;
Axt, Sabine ;
Benton, Bret M. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) :2198-2200
[8]  
Mendes RE, 2014, DIAGN MICROBIOL INFE, V81, P275
[9]   Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States [J].
Mendes, Rodrigo E. ;
Sader, Helio S. ;
Flamm, Robert K. ;
Farrell, David J. ;
Jones, Ronald N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (03) :1811-1814
[10]   Worldwide Appraisal and Update (2010) of Telavancin Activity Tested against a Collection of Gram-Positive Clinical Pathogens from Five Continents [J].
Mendes, Rodrigo E. ;
Sader, Helio S. ;
Farrell, David J. ;
Jones, Ronald N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (07) :3999-4004